The specifics, since they change the answer: a 31G needle · 2.5 mg/mL.
I would like the arithmetic checked rather than the conclusion asserted.
I have deliberately not used an online calculator because I want to be able to check the result.
Can someone walk through the arithmetic step by step?
At 2.5 mg/mL every microlitre left behind is 2.5 µg, so a 50 µL hub costs 0.125 mg per draw and a 5 µL fixed-needle barrel costs 0.0125 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 1.25 mg gone, which at 2.5 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 6.3 per cent; against a 0.25 mg dose it is 50 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 31G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
Dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.
Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsIn practice, dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
It helps to be literal here: draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
If cost matters, this is the first thing to change, not the last.
Start from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Before anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.
The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.
The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.
Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.
Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.
edited 29 Nov 2024 by petra_hovland — added the citation requested in comments
The short answer is that dead space is small in absolute terms and huge as a fraction of a small dose, which is why it feels like a rounding error and behaves like a systematic loss.
Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.